Sanofi (NASDAQ:SNY) Stock Rating Raised to “Buy” at Wall Street Zen

Sanofi (NASDAQ:SNY) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities analysts have also weighed in on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. DZ Bank restated a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Wolfe Research initiated coverage on Sanofi in a research note on Friday, October 9th. They issued a “peer perform” rating for the company. Berenberg Bank restated a “buy” rating on shares of Sanofi in a report on Monday, October 5th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Up 0.3%

NASDAQ SNY opened at $47.04 on Friday. The company has a market capitalization of $114.05 billion, a P/E ratio of 23.29, a PEG ratio of 1.25 and a beta of 0.31. The company’s 50 day simple moving average is $42.30 and its 200 day simple moving average is $44.34. Sanofi has a 12 month low of $39.07 and a 12 month high of $52.68. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.64.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.48. The firm had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The company’s revenue was up 16.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.91 EPS. Equities research analysts expect that Sanofi will post 5.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently modified their holdings of SNY. Manning & Napier Advisors LLC boosted its stake in shares of Sanofi by 728,134.8% during the 1st quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after purchasing an additional 1,194,141 shares during the last quarter. Bank of America Corp DE grew its position in shares of Sanofi by 11.0% in the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after acquiring an additional 940,342 shares during the period. Regal Partners Ltd grew its holdings in shares of Sanofi by 33.2% during the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after purchasing an additional 633,782 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Sanofi by 17.5% in the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock valued at $152,011,000 after purchasing an additional 470,882 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its position in shares of Sanofi by 399.3% in the first quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company’s stock worth $15,270,000 after purchasing an additional 253,465 shares during the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world.

Sanofi traces its origins to a company established in France in 1973.